Heather Preston
Chair
- Non-Executive Director of Oxford Biomedica, Oxford Nanopore Technologies plc and of Aligos Therapeutics
- Senior Advisor of TPG Biotech
- Served as a Director on the Boards of Oxford Science Enterprises plc, Karuna Pharmaceuticals and Akouos Inc.
- Over 30 years of experience in healthcare, as a scientist, physician and management consultant and an investor in life sciences and biotechnology for more than 20 years.
- Degree in Medicine from the University of Oxford
Christian Jung
Investor Director, Dementia Discovery Fund
- Partner at SV Health Investors and co-lead for the Dementia Discovery Fund (DDF) currently representing the fund on the Boards of Harness Therapeutics Ltd, Amphista Therapeutics Ltd, Leal Therapeutics, LLC and LoQus23 Therapeutics Ltd
- Previously Principal with Wellington Partners and Senior Investment Manager for High-Tech Gründerfonds (HTGF)
- MSc degree in Molecular Biotechnology
- PhD with distinction in Medical Science and Technology from the Technical University of Munich
Jiaping Gu
Investor Director, Takeda Ventures
- Takeda Ventures - Partner
- 8+ years of experience in public and private life science investments. Previously Vice President at Hillhouse Capital covering private stage biotech investments in the US and Europe
- 10+ years of research experience focusing on neurodegeneration as a scientist in the pharmaceutical industry and academic institutions.
- Ph.D. in Neuroscience from Rutgers University and B.S. in Biological Sciences from Tsinghua University
Mary Canning
Observer, Epidarex Capital
- Partner: Epidarex Capital
- Director: Caldan Therapeutics, LUNAC Therapeutics and Glasgow University Holdings Ltd
- Commercialised academic research with MRC Technology
- PhD and postdoctoral research in molecular biology
Dirk Landgraf
Observer, Dementia Discovery Fund
- SV Health Investors: Principal and Dementia Discovery Fund
- Biogen: External Innovation and Business Development
- Whitehead/MIT: Postdoctoral research on protein misfolding toxicities
- PhD Systems Biology, Harvard Medical School
Haruhito Tsutsui
Observer, Ono Venture Investment
- Investment Director: Ono Venture Investment
- Senior Manager: Discovery Research Alliance, Neurology Research Center, Ono Pharmaceutical / Ono Pharma UK
- Researcher: Biomarker Research, Ono Pharmaceutical
- PhD in pharmacology, bioanalysis
Paulo Fontoura
Independent Director
- Roche: Senior Vice President and Global Head of Clinical Development for Neuroscience, Immunology, Ophthalmology, Rare and Infectious Diseases
- Fellow of the American Academy of Neurology
- Postdoctoral Fellowship Stanford University
- MD PhD New University of Lisbon, Neurology training, summa cum laude
Jan Thirkettle
CEO Director
- Freeline Therapeutics – CEO and CDO
- GSK – Discovery to Manufacturing
- Strimvelis – the first ex vivo gene therapy approved by EMA
- MA in Chemistry and a DPhil in Biological Chemistry, University of Oxford